Weak pound buoys GSK but drugmaker warns on 2017 generic threat

LONDON (Reuters) - GlaxoSmithKline sales and profits jumped in the fourth quarter, helped by falling sterling, but the drugmaker cautioned profit growth could be impacted in 2017 by generic competition to its top-selling lung drug Advair.

from Reuters: Top News http://uk.reuters.com/article/uk-gsk-results-idUKKBN15N1CZ?feedType=RSS&feedName=topNews